Notably, the involvement of ANRIL in cancer may be context-dependent, as a specific SNP in melanoma was found to downregulate ANRIL expression, whereas a different ANRIL mutation was found to increase its expression in glioma [338]. This evidence concerns the gene CDKN2B-AS1 and glioma.